Trials / Completed
CompletedNCT05155644
Safety of Therapeutic Step-down in Neuromyelitis Optica
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 947 (actual)
- Sponsor
- University Hospital, Strasbourg, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Neuromyelitis Optica (NMO) is a neuroinflammatory disease related to multiple sclerosis (MS). It affects young subjects and causes a lot of handicap without treatment. Thus, aggressive treatments are frequently introduced early in the life of patients and maintained over the long term. A long duration of treatment exposes to iatrogenism. Therapeutic de-escalation trials in MS or other autoimmune diseases show rebound phenomena. In the NMO, there are no published data on the tolerance of desescalations to guide such strategies.
Conditions
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2021-11-30
- Completion
- 2021-12-31
- First posted
- 2021-12-13
- Last updated
- 2022-01-21
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05155644. Inclusion in this directory is not an endorsement.